Replies to post #105837 on Biotech Values

[Bulbaman]

ROSG - not following closely, just saw this (and then looked at their Q2 revenues to see that their three commercial tests aren't big sellers. Perhaps insurance companies will not yet pay for them):

Rosetta clearly doesn’t have the resources to build a diagnostics business. And their partnership with the Prometheus Labs has been a disaster, with the companies now involved in a legal battle. On the more optimistic side, Rosetta does have some valuable microRNA IP which could easily be worth quite a bit more than its $17 million market cap.